SIGN UP
LOG IN
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga·06/02/2025 12:07:43
Listen to the news
Gainers
- Lyra Therapeutics (NASDAQ:LYRA) shares moved upwards by 463.3% to $27.77 during Monday's pre-market session. The market value of their outstanding shares is at $36.8 million.
- Vera Therapeutics (NASDAQ:VERA) shares increased by 62.58% to $30.81. The company's market cap stands at $1.9 billion.
- Plus Therapeutics (NASDAQ:PSTV) stock increased by 39.8% to $0.4. The company's market cap stands at $2.3 million. As per the press release, Q1 earnings came out yesterday.
- Basel Medical Group (NASDAQ:BMGL) stock increased by 39.09% to $8.46. The market value of their outstanding shares is at $158.8 million.
- Kymera Therapeutics (NASDAQ:KYMR) stock rose 34.95% to $40.0. The company's market cap stands at $2.6 billion.
- Instil Bio (NASDAQ:TIL) shares moved upwards by 30.9% to $35.28. The company's market cap stands at $231.4 million.
Losers
- Telomir Pharmaceuticals (NASDAQ:TELO) stock declined by 24.9% to $1.46 during Monday's pre-market session. The company's market cap stands at $43.4 million.
- Xilio Therapeutics (NASDAQ:XLO) stock decreased by 21.98% to $0.83. The company's market cap stands at $43.2 million.
- Reshape Lifesciences (NASDAQ:RSLS) shares fell 19.27% to $3.96. The market value of their outstanding shares is at $2.9 million.
- Silexion Therapeutics (NASDAQ:SLXN) stock fell 16.21% to $0.87. The company's market cap stands at $7.5 million.
- Regencell Bioscience (NASDAQ:RGC) stock fell 12.21% to $770.0. The market value of their outstanding shares is at $10.0 billion.
- Lucid Diagnostics (NASDAQ:LUCD) shares fell 10.8% to $1.24. The company's market cap stands at $125.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.